Associated Papers
Deleterious and ethnic-related BRCA1/2 mutations in tissue and blood of Egyptian colorectal cancer patients and its correlation with human papillomavirus.
Youssef ASE et al.
Clinical and Experimental Medicine, 2023
Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
Lai Z et al.
Bmc Cancer, 2022
34979999 (PubMed )
Supplement: 12885_2021_9082_MOESM1_ESM.pdf
Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study.
Zhang R et al.
Breast Cancer (tokyo, Japan), 2021
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
Vos JR et al.
Journal of the National Cancer Institute, 2020
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
32976510 (PubMed )
Supplement: pone.0237802.s009.zip › S5_S7_Tables_Precision_Line_data_for_targeted_CDx_variants.xlsx › sheet_1
FANCD2 limits replication stress and genome instability in cells lacking BRCA2.
Michl J et al.
Nature Structural & Molecular Biology, 2016
27322732 (PubMed )
Supplement: NIHMS69022-supplement-Supplementary_Tables.pdf
Select a paper to view details